Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016

Details for Mechanism ID: 16763
Country/Region: Tanzania
Year: 2016
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $31,418,623 Additional Pipeline Funding: $2,529,998

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,669,331
Care: TB/HIV (HVTB) $724,824
Care: Pediatric Care and Support (PDCS) $530,604
Laboratory Infrastructure (HLAB) $170,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $5,078,369
Prevention: HIV Testing and Counseling (HVCT) $1,366,218
Sexual Prevention: Other Sexual Prevention (HVOP) $1,382,912
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $4,307,280
Treatment: Adult Treatment (HTXS) $13,982,065
Treatment: Pediatric Treatment (PDTX) $1,207,020
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV_DSD Age/Sex: 10-14 Female 2017 3,179
GEND_GBV_DSD Age/Sex: 10-14 Male 2017 2,265
GEND_GBV_DSD Age/Sex: 15-19 Female 2017 1,688
GEND_GBV_DSD Age/Sex: 15-19 male 2017 1,643
GEND_GBV_DSD Age/Sex: 20-24 Female 2017 1,289
GEND_GBV_DSD Age/Sex: 20-24 Male 2017 1,064
GEND_GBV_DSD Age/Sex: 25-49 Female 2017 1,618
GEND_GBV_DSD Age/Sex: 25-49 Male 2017 1,372
GEND_GBV_DSD Age/Sex: 50+ Female 2017 193
GEND_GBV_DSD Age/Sex: 50+ Male 2017 159
GEND_GBV_DSD Age/Sex: <10 Female 2017 2,032
GEND_GBV_DSD Age/Sex: <10 Male 2017 1,848
GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 2017 768
GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 12,232
GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 2017 6,118
GEND_GBV_DSD Number of people receiving post-GBV care 2017 18,350
GEND_GBV_DSD Sum of Age/Sex Disaggregates 2017 9,324
HTC_TST_DSD Age/sex: 1-9 2017 21,831
HTC_TST_DSD Age/sex: 10-14 Female 2017 1,081
HTC_TST_DSD Age/sex: 10-14 Male 2017 12,770
HTC_TST_DSD Age/sex: 15-19 Female 2017 6,404
HTC_TST_DSD Age/sex: 15-19 Male 2017 4,338
HTC_TST_DSD Age/sex: 20-24 Female 2017 8,598
HTC_TST_DSD Age/sex: 20-24 Male 2017 3,058
HTC_TST_DSD Age/sex: 25-49 Female 2017 34,054
HTC_TST_DSD Age/sex: 25-49 Male 2017 30,486
HTC_TST_DSD Age/sex: 50+ Female 2017 4,836
HTC_TST_DSD Age/sex: 50+ Male 2017 6,061
HTC_TST_DSD Age/sex: <1 2017 3,038
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 430,820
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 224,686
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 77,896
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 145,970
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 1,015,927
HTC_TST_DSD Service Delivery Point (Community): Homebased testing 2017 63,311
HTC_TST_DSD Service Delivery Point (Community): Mobile testing 2017 81,008
HTC_TST_DSD Service Delivery Point (Facility): Inpatient 2017 25,593
HTC_TST_DSD Service Delivery Point (Facility): Other PITC 2017 23,053
HTC_TST_DSD Service Delivery Point (Facility): Outpatient 2017 264,568
HTC_TST_DSD Service Delivery Point (Facility): Pediatric 2017 112,281
HTC_TST_DSD Service Delivery Point (Facility): PMTCT 2017 250,907
HTC_TST_DSD Service Delivery Point (Facility): VMMC 2017 195,206
HTC_TST_DSD Sum of Age/Sex disaggregates 2017 111,686
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2017 655,506
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2017 223,866
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2017 879,372
HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 2017 67
HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 2017 163
HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 2017 603
HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 2017 251
HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Female 2017 829
HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 2017 271
HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Female 2017 3,190
HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 2017 1,724
HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Female 2017 453
HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 2017 323
HTC_TST_DSD Test Result by Age: Positive: 1-9 2017 472
HTC_TST_DSD Test Result by Age: Positive: <1 2017 49
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 25,117
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 16,340
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Female 2017 2,204
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Male 2017 2,906
KP_PREV_DSD By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 8,125
KP_PREV_DSD By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 6,288
KP_PREV_DSD By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) 2017 928
KP_PREV_DSD By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 910
KP_PREV_DSD Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 7,198
KP_PREV_DSD Total estimated number of key population in the catchment area 2017 9,053
LAB_PT_DSD CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 24
LAB_PT_DSD CD4: Number of laboratories that participate in this PT program 2017 39
LAB_PT_DSD CD4: Number of laboratories that perform this testing 2017 68
LAB_PT_DSD Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT_DSD Early infant diagnostics: Number of laboratories that participate in this PT program 2017 2
LAB_PT_DSD Early infant diagnostics: Number of laboratories that perform this testing 2017 1
LAB_PT_DSD HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 268
LAB_PT_DSD HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 339
LAB_PT_DSD HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 142
LAB_PT_DSD HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT_DSD HIV viral load: Number of laboratories that participate in this PT program 2017 2
LAB_PT_DSD HIV viral load: Number of laboratories that perform this testing 2017 1
LAB_PT_DSD TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 11
LAB_PT_DSD TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 21
LAB_PT_DSD TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 70
LAB_PT_DSD TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT_DSD TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program 2017 2
LAB_PT_DSD TB diagnostics (Culture/DST): Number of laboratories that perform this testing 2017 2
LAB_PT_DSD TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 4
LAB_PT_DSD TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 6
LAB_PT_DSD TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 11
LAB_PT_TA CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT_TA CD4: Number of laboratories that participate in this PT program 2017 12
LAB_PT_TA CD4: Number of laboratories that perform this testing 2017 13
LAB_PT_TA HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 251
LAB_PT_TA HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 195
LAB_PT_TA HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 409
LAB_PT_TA TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT_TA TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 9
LAB_PT_TA TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 38
LAB_PT_TA TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 1
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2017 4,194
PMTCT_ART_DSD New on ART 2017 9,290
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 241,833
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2017 10,035
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2017 3,463
PMTCT_EID_DSD Number of infants with a positive virological test result within 12 months of birth 2017 109
PMTCT_EID_DSD Number of infants with a positive virological test result within 2 months of birth 2017 293
PMTCT_EID_DSD Sum of Infant Age disaggregates 2017 13,498
PMTCT_STAT_DSD By: Known positives at entry 2017 4,420
PMTCT_STAT_DSD By: Number of new positives identified 2017 9,768
PMTCT_STAT_DSD Number of new ANC and L&D clients 2017 254,579
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 241,833
PMTCT_STAT_DSD Required only for DREAMS Countries - By Number of known positives: 15-19 2017 178
PMTCT_STAT_DSD Required only for DREAMS Countries - By Number of known positives: 20-24 2017 267
PMTCT_STAT_DSD Required only for DREAMS Countries - By Number of known positives: 25-49 2017 397
PMTCT_STAT_DSD Required only for DREAMS Countries - By Number of known positives: <15 2017 93
PMTCT_STAT_DSD Required only for DREAMS Countries - By Number of new positives: 15-19 2017 444
PMTCT_STAT_DSD Required only for DREAMS Countries - By Number of new positives: 20-24 2017 681
PMTCT_STAT_DSD Required only for DREAMS Countries - By Number of new positives: 25-49 2017 955
PMTCT_STAT_DSD Required only for DREAMS Countries - By Number of new positives: <15 2017 240
PMTCT_STAT_DSD Required only for DREAMS Countries - Denominator: 20-24 2017 11,017
PMTCT_STAT_DSD Required only for DREAMS Countries - Denominator: 25-49 2017 15,486
PMTCT_STAT_DSD Required only for DREAMS Countries - Denominator: <15 2017 3,358
PMTCT_STAT_DSD Required only for DREAMS Countries - Denominator: <15-19 2017 6,215
PMTCT_STAT_DSD Sum of Positives Status disaggregates 2017 14,188
PP_PREV_DSD Aggregated Age/sex: 15+ Female 2017 24,960
PP_PREV_DSD Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 24,960
PP_PREV_DSD Total number of people in the target population 2017 30,561
TB_SCREENDX_DSD Screen Result: Screened Positive for TB 2017 2,799
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Female 2017 111,864
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Male 2017 55,310
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Female 2017 5,977
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Male 2017 5,260
TB_SCREENDX_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 178,411
TB_SCREENDX_DSD [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 2,799
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 44
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 2,460
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 295
TX_CURR_DSD Age/Sex: 10-14 Female 2017 418
TX_CURR_DSD Age/Sex: 10-14 Male 2017 429
TX_CURR_DSD Age/Sex: 15-19 Female 2017 1,805
TX_CURR_DSD Age/Sex: 15-19 Male 2017 942
TX_CURR_DSD Age/Sex: 20-24 Female 2017 3,288
TX_CURR_DSD Age/Sex: 20-24 Male 2017 491
TX_CURR_DSD Age/Sex: 25-49 Female 2017 19,168
TX_CURR_DSD Age/Sex: 25-49 Male 2017 8,647
TX_CURR_DSD Age/Sex: 50+ Female 2017 2,215
TX_CURR_DSD Age/Sex: 50+ Male 2017 2,027
TX_CURR_DSD Age/Sex: <1 2017 70
TX_CURR_DSD Age/Sex: <1-9 2017 1,483
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2017 89,500
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2017 47,943
TX_CURR_DSD Aggregated Age/Sex: <15 Female 2017 4,957
TX_CURR_DSD Aggregated Age/Sex: <15 Male 2017 4,391
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2017 187,774
TX_CURR_DSD Sum of age/sex disaggregates 2017 2,747
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2017 137,443
TX_CURR_DSD Sum of Aggregated Age/Sex <15 2017 9,348
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2017 146,791
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2017 24,160
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2017 13,253
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Female 2017 1,976
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Male 2017 1,652
TX_NEW_DSD By Age/Sex: 1-9 2017 394
TX_NEW_DSD By Age/Sex: 10-14 Female 2017 56
TX_NEW_DSD By Age/Sex: 10-14 Male 2017 116
TX_NEW_DSD By Age/Sex: 15-19 Female 2017 746
TX_NEW_DSD By Age/Sex: 15-19 Male 2017 290
TX_NEW_DSD By Age/Sex: 20-24 Female 2017 1,016
TX_NEW_DSD By Age/Sex: 20-24 Male 2017 162
TX_NEW_DSD By Age/Sex: 25-49 Female 2017 5,152
TX_NEW_DSD By Age/Sex: 25-49 Male 2017 3,641
TX_NEW_DSD By Age/Sex: 50+ Female 2017 732
TX_NEW_DSD By Age/Sex: 50+ Male 2017 691
TX_NEW_DSD By Age/Sex: <1 2017 70
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 54,107
TX_NEW_DSD Sum of Age/Sex disaggregates 2017 12,602
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2017 41,041
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Female 2017 76,223
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Male 2017 40,995
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Female 2017 4,610
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Male 2017 4,102
TX_PVLS_DSD Denominator: Indication: Routine 2017 54,107
TX_PVLS_DSD Denominator: Indication: Targeted 2017 71,823
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 125,930
TX_PVLS_DSD Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 113,518
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Female 2017 68,682
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Male 2017 36,945
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Female 2017 4,180
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Male 2017 3,711
TX_PVLS_DSD Numerator: Indication: Routine 2017 48,833
TX_PVLS_DSD Numerator: Indication: Targeted 2017 64,685
TX_RET_DSD Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 141
TX_RET_DSD Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 104
TX_RET_DSD Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 22
TX_RET_DSD Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 13
TX_RET_DSD Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 40
TX_RET_DSD Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 28
TX_RET_DSD Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 346
TX_RET_DSD Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 262
TX_RET_DSD Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 162
TX_RET_DSD Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 119
TX_RET_DSD Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 439
TX_RET_DSD Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 331
TX_RET_DSD Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 56
TX_RET_DSD Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 41
TX_RET_DSD Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,026
TX_RET_DSD Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,522
TX_RET_DSD Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,249
TX_RET_DSD Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 938
TX_RET_DSD Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 285
TX_RET_DSD Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 211
TX_RET_DSD Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 253
TX_RET_DSD Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 189
TX_RET_DSD Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 24
TX_RET_DSD Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 32
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 13,085
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 9,807
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7,681
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,746
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,245
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 918
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,170
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 861
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 21,114
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 28,232
VMMC_CIRC_DSD By Age: 10-14 2017 97,600
VMMC_CIRC_DSD By Age: 15-19 2017 45,530
VMMC_CIRC_DSD By Age: 20-24 2017 22,649
VMMC_CIRC_DSD By Age: 25-29 2017 29,427
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2017 195,206
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 195,206
VMMC_CIRC_DSD Sum of age disaggregates (FY15-Current) 2017 195,206
VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 2017 165,779
Cross Cutting Budget Categories and Known Amounts Total: $943,493
Gender: Gender Based Violence (GBV) $413,493
GBV Prevention
Implementation
Monitoring and Evaluation
Post GBV Care
Implementation
Capacity building
Monitoring and Evaluation
Water $50,000
Motor Vehicles: Purchased $480,000